Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMRNASDAQ:LVTXNASDAQ:NGNENASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$1.91+3.5%$2.54$1.61▼$11.20$121.97M0.91672,476 shs1.09 million shsLVTXLAVA Therapeutics$1.31+6.5%$1.20$0.85▼$3.20$34.46M0.46163,107 shs101,891 shsNGNENeurogene$11.49+6.7%$14.46$6.88▼$74.49$171.55M1.46225,296 shs190,038 shsSCPHscPharmaceuticals$2.57+0.8%$2.93$1.94▼$5.65$129.23M0.38354,104 shs249,629 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics+3.53%+7.02%-19.62%-42.96%-72.98%LVTXLAVA Therapeutics+6.50%+21.30%+1.55%+39.36%-55.44%NGNENeurogene+6.69%+28.09%-27.51%-30.78%-65.84%SCPHscPharmaceuticals+0.78%+27.23%-15.74%-21.65%-41.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLRMRLarimar Therapeutics3.2375 of 5 stars4.63.00.00.03.51.70.0LVTXLAVA Therapeutics2.3894 of 5 stars3.05.00.00.03.20.00.6NGNENeurogene1.9784 of 5 stars3.61.00.00.01.11.71.3SCPHscPharmaceuticals3.7392 of 5 stars3.52.00.04.21.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 3.10Buy$19.63930.18% UpsideLVTXLAVA Therapeutics 2.00Hold$3.17141.73% UpsideNGNENeurogene 3.13Buy$47.20310.79% UpsideSCPHscPharmaceuticals 3.00Buy$14.00444.75% UpsideCurrent Analyst Ratings BreakdownLatest LVTX, LRMR, NGNE, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.003/31/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.503/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/25/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.003/20/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $12.003/20/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/ALVTXLAVA Therapeutics$11.98M2.88N/AN/A$1.95 per share0.67NGNENeurogene$925K185.45N/AN/A$14.51 per share0.79SCPHscPharmaceuticals$36.33M3.56N/AN/A$1.04 per share2.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$36.95M-$1.30N/AN/AN/AN/A-35.87%-32.37%5/8/2025 (Estimated)LVTXLAVA Therapeutics-$41.97M-$0.93N/AN/AN/AN/A-62.22%-29.37%5/20/2025 (Estimated)NGNENeurogene-$36.32M-$4.27N/AN/AN/AN/A-32.81%-27.96%5/9/2025 (Estimated)SCPHscPharmaceuticals-$54.81M-$1.90N/AN/AN/A-264.60%-244.93%-68.56%5/13/2025 (Estimated)Latest LVTX, LRMR, NGNE, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SCPHscPharmaceuticals-$0.28N/AN/AN/A$11.63 millionN/A5/9/2025Q1 2025NGNENeurogene-$1.05N/AN/AN/AN/AN/A5/8/2025Q1 2025LRMRLarimar Therapeutics-$0.42N/AN/AN/AN/AN/A3/28/2025Q4 2024LVTXLAVA Therapeutics-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 million3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A13.1013.10LVTXLAVA TherapeuticsN/A5.365.36NGNENeurogeneN/A9.099.09SCPHscPharmaceuticals1.668.086.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%LVTXLAVA TherapeuticsN/ANGNENeurogene52.37%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics3.50%LVTXLAVA Therapeutics0.79%NGNENeurogene9.92%SCPHscPharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics3064.03 million61.57 millionOptionableLVTXLAVA Therapeutics6026.31 million26.08 millionOptionableNGNENeurogene9014.93 million13.38 millionOptionableSCPHscPharmaceuticals3050.28 million47.28 millionOptionableLVTX, LRMR, NGNE, and SCPH HeadlinesRecent News About These CompaniesWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 9.58%April 11, 2025 | aaii.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 9.30%April 9, 2025 | aaii.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 11.41%April 2, 2025 | aaii.comCraig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)March 22, 2025 | markets.businessinsider.comscPharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results with Major FDA Approval for FUROSCIXMarch 22, 2025 | nasdaq.comscPharmaceuticals (NASDAQ:SCPH) Given New $12.00 Price Target at Maxim GroupMarch 21, 2025 | marketbeat.comscPharmaceuticals Full Year 2024 Earnings: In Line With ExpectationsMarch 21, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for scPharmaceuticals (NASDAQ:SCPH)March 21, 2025 | marketbeat.comscPharmaceuticals price target lowered to $12 from $20 at MaximMarch 21, 2025 | markets.businessinsider.comscPharmaceuticals (NASDAQ:SCPH) Issues Earnings ResultsMarch 20, 2025 | marketbeat.comscPharmaceuticals (NASDAQ:SCPH) Announces Quarterly Earnings ResultsMarch 20, 2025 | marketbeat.comQ4 2024 scPharmaceuticals Inc Earnings CallMarch 20, 2025 | finance.yahoo.comscPharmaceuticals reports Q 4EPS (35c), consensus (39c)March 20, 2025 | markets.businessinsider.comscPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025March 19, 2025 | msn.comScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue EstimatesMarch 19, 2025 | zacks.comscPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 19, 2025 | gurufocus.comscPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | globenewswire.comscPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025March 12, 2025 | globenewswire.comThe week in pharma: action, reaction and insight – week to March 7March 9, 2025 | thepharmaletter.comWearable Furosemide Delivery System Approved for CKD PatientsMarch 7, 2025 | empr.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLVTX, LRMR, NGNE, and SCPH Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$1.90 +0.07 (+3.53%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$1.90 -0.01 (-0.52%) As of 04/17/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.LAVA Therapeutics NASDAQ:LVTX$1.31 +0.08 (+6.50%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.32 +0.01 (+0.76%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Neurogene NASDAQ:NGNE$11.49 +0.72 (+6.69%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$11.12 -0.37 (-3.18%) As of 04/17/2025 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.scPharmaceuticals NASDAQ:SCPH$2.57 +0.02 (+0.78%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.57 0.00 (0.00%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
